Physician profile
Daniel Tannenbaum
NPI 1922454925
$994.70
in general payments reported to CMS, 2019-2025
22 companies · $297 in 2025
The $297 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.08 · 2021: $150 · 2022: $17.12 · 2023: $185 · 2024: $334 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $816.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $174.68 | 2021-2023 | Reblozyl |
| Novartis Pharmaceuticals Corporation | $156.72 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $119.82 | 2023-2024 | Gemtesa |
| Biotissue Holdings INC. | $117.07 | 2025 | |
| Blue Earth Diagnostics | $49.32 | 2025 | Posluma |
| Janssen Biotech, INC. | $41.71 | 2024-2025 | Rybrevant |
| Merck Sharp & Dohme LLC | $29.15 | 2024 | Keytruda |
| Myriad Genetic Laboratories, INC. | $25.71 | 2024 | Myrisk |
| Legend Biotech USA INC. | $25.02 | 2024 | |
| Rigel Pharmaceuticals, INC. | $24.78 | 2024 | Tavalisse, Rezlidhia |
| Genentech USA, INC. | $24.11 | 2023 | Polivy, Columvi |
| Axonics, INC. | $23.93 | 2023 | Axonics |
| Pharmacosmos Therapeutics INC. | $22.65 | 2025 | Monoferric |
| Abbvie INC. | $21.38 | 2024 | |
| Sobi, INC | $20.78 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $20.55 | 2024 | Sylvant |
| Deciphera Pharmaceuticals INC. | $20.33 | 2023 | Qinlock |
| Puma Biotechnology, INC. | $18.43 | 2025 | |
| Amgen INC. | $17.12 | 2022 | |
| Pfizer INC. | $15.87 | 2023 | |
| Tolmar, INC. | $14.49 | 2024 | |
| Agios Pharmaceuticals, INC. | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Tannenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.